Nuvectis Pharma, Inc.
NVCTHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeNuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Valued at $654.5M, NVCT is a small-cap name in its sector. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Market Cap
$654.5M
Beta
-0.24
P/E (TTM)
—
P/E (Fwd)
-20.89
EPS (TTM)
$-1.31
EPS (Fwd)
$-0.96
ROE
-214.6%
ROA
-73.1%
Cash
$22.2M
Total Debt
$0
Free CF
-$8.9M
52W Change
223.4%
Annual Financials
Cash vs Debt
Where NVCT stands vs its 150-day and 200-day moving averages
As of the September 11, 2026 close, NVCT finished 63.21% above its 150-day moving average ($13.78) and 83.44% above its 200-day moving average ($12.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NVCT overbought or oversold?
At the September 11, 2026 close, NVCT's RSI(14) was 45.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Nuvectis Pharma, Inc. reports $22.2M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$8.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -214.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of -0.24 suggests NVCT is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Nuvectis Pharma, Inc.'s trajectory.